These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1613007)

  • 41. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoimmune phenomena in patients with myelodysplastic syndromes.
    Enright H; Miller W
    Leuk Lymphoma; 1997 Feb; 24(5-6):483-9. PubMed ID: 9086438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population.
    Marisavljević D; Kraguljac N; Rolović Z
    Med Oncol; 2006; 23(3):385-91. PubMed ID: 17018896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
    Chamuleau ME; Westers TM; van Dreunen L; Groenland J; Zevenbergen A; Eeltink CM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2009 Apr; 94(4):496-506. PubMed ID: 19229054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The immune landscape of myelodysplastic syndromes.
    Fozza C; Crobu V; Isoni MA; Dore F
    Crit Rev Oncol Hematol; 2016 Nov; 107():90-99. PubMed ID: 27823655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenotypic and genotypic analyses of blastic cell population suggest that pure B-lymphoblastic leukemia may arise from myelodysplastic syndrome.
    Pajor L; Matolcsy A; Vass JA; Méhes G; Marton E; Szabó F; Iványi JL
    Leuk Res; 1998 Jan; 22(1):13-7. PubMed ID: 9585074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells.
    Al Ustwani O; Francis J; Wallace PK; Ambrus J; Wetzler M
    Leuk Res; 2011 May; 35(5):e35-6. PubMed ID: 21247634
    [No Abstract]   [Full Text] [Related]  

  • 48. Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.
    Kiladjian JJ; Fenaux P; Caignard A
    Leukemia; 2007 Nov; 21(11):2237-9. PubMed ID: 17957204
    [No Abstract]   [Full Text] [Related]  

  • 49. A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.
    Giannouli S; Voulgarelis M
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1679-88. PubMed ID: 25308147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Auto-immune diseases and cancers. Second part: auto-immune diseases complicating cancers and their treatment].
    Pasquet F; Pavic M; Ninet J; Hot A
    Rev Med Interne; 2014 Oct; 35(10):656-63. PubMed ID: 25106665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical application of whole-genome sequencing in patients with primary immunodeficiency.
    Mousallem T; Urban TJ; McSweeney KM; Kleinstein SE; Zhu M; Adeli M; Parrott RE; Roberts JL; Krueger B; Buckley RH; Goldstein DB
    J Allergy Clin Immunol; 2015 Aug; 136(2):476-9.e6. PubMed ID: 25981738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease.
    Lougaris V; Tabellini G; Vitali M; Baronio M; Patrizi O; Tampella G; Biasini A; Moratto D; Parolini S; Plebani A
    J Allergy Clin Immunol; 2015 Jun; 135(6):1641-3. PubMed ID: 25605273
    [No Abstract]   [Full Text] [Related]  

  • 53. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.
    Barrett AJ; Sloand E
    Haematologica; 2009 Apr; 94(4):449-51. PubMed ID: 19336747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression and function of B7 family molecules on blasts of patients with myelodysplastic syndromes.
    Tamura H
    J Nippon Med Sch; 2007 Feb; 74(1):85-6. PubMed ID: 17384486
    [No Abstract]   [Full Text] [Related]  

  • 55. Myelodysplastic syndrome with signs of auto-immune disease in a patient with renal allograft.
    Förster E; Birnbacher R; Mann G; Balzar E; Radaszkiewicz T; Urbanek R
    Eur J Pediatr; 1998 Apr; 157(4):351. PubMed ID: 9578978
    [No Abstract]   [Full Text] [Related]  

  • 56. Correlation of elevated plasma soluble IL-2 receptor levels with defective NK and CD8+ T-cells in myelodysplastic syndromes: is it part of a spectrum?
    Demeter J; Schmid M; Vargha P; Porzsolt F
    Leuk Res; 1995 Aug; 19(8):583-4. PubMed ID: 7658706
    [No Abstract]   [Full Text] [Related]  

  • 57. [Immunologic disorders in patients with primary myelodysplasias].
    Soboleva SS; Ivanova TI; Loriia SS; Eremkina EI; Tupitsin NN
    Gematol Transfuziol; 1988 Apr; 33(4):10-4. PubMed ID: 3396836
    [No Abstract]   [Full Text] [Related]  

  • 58. [Interaction of monoclonal antibodies IKO-11 with peripheral blood lymphocytes in myelodysplastic syndromes].
    Ivanova TI; Tupitsin NN; Baryshnikov AIu; Derbeneva LI; Savel'eva EV
    Gematol Transfuziol; 1986 May; 31(5):6-9. PubMed ID: 3721182
    [No Abstract]   [Full Text] [Related]  

  • 59. Natural Killer Cells and Thyroid Diseases.
    Lee EK; Sunwoo JB
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):132-137. PubMed ID: 31257741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy.
    Copplestone JA; Mufti GJ; Hamblin TJ; Oscier DG
    Br J Haematol; 1986 May; 63(1):149-59. PubMed ID: 3707860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.